和誉医药2025年上半年净利润3.28亿元;信达生物小分子GLP-1R激动剂在美获批临床

Ofweek光电信息网
Aug 06, 2025

创新药企财报季来临。8月4日,和誉医药公布2025年半年报。报告期内,得益于默克行权,公司实现收入6.12亿元,同比增长23%;净利润3.28亿元,同比增长59%。截至6月30日,公司账上现金余额超23亿元。信达生物深入减肥药布局。8月5日,信达生物宣布,口服小分子GLP-1R激动剂IBI3032获美国FDA新药临床试验申请(IND)批准。IBI3032的1期临床试验将在中美同步推进,将于2025...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10